KYBELLA® is the first FDA approved non-surgical injection for improving the appearance of moderate to severe submental fullness, commonly referred to as double chin. KYBELLA® is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected into subcutaneous fat, KYBELLA® causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
KYBELLA® (deoxycholic acid) injection 10 mg/mL is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
KYBELLA is administered by a trained physician who injects the product under a patient’s chin to destroy fat cells, improving the appearance of the patient’s chin area. Up to six treatments may be administered per patient no less than one month apart, and each in-office treatment session lasts approximately twenty minutes.
KYBELLA joins BOTOX® Cosmetic, JUVEDERM® XC, JUVEDERM VOLUMA® XC and LATISSE® as part of the Allergan company, which has recently merged with Pfizer.
Unretouched photos of clinical trial patient
taken before and after treatment with KYBELLA®.
Sex:F Age: 39
Weight (before): 209.8lbs.
Weight (after): 214.6lbs.
Individual results may vary